Endocrine-Related Cancer

Công bố khoa học tiêu biểu

* Dữ liệu chỉ mang tính chất tham khảo

Sắp xếp:  
The dual role of filamin A in cancer: can't live with (too much of) it, can't live without it
Endocrine-Related Cancer - Tập 20 Số 6 - Trang R341-R356 - 2013
Rosalinda M Savoy, P. Ghosh
Filamin A (FlnA) has been associated with actin as cytoskeleton regulator. Recently its role in the cell has come under scrutiny for FlnA's involvement in cancer development. FlnA was originally revealed as a cancer-promoting protein, involved in invasion and metastasis. However, recent studies have also found that under certain conditions, it prevented tumor formation or progression, conf...... hiện toàn bộ
Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide
Endocrine-Related Cancer - Tập 21 Số 5 - Trang 705-714 - 2014
Matthew H. Kulke, Thomas M. O’Dorisio, Alexandria T. Phan, Emily K. Bergsland, Linda Law, Phillip Banks, Joel Freiman, Kenneth Frazier, Jessica Jackson, James C. Yao, Larry K. Kvols, Pablo Lapuerta, Brian Zambrowicz, Douglas Fleming, Arthur Sands
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial
Endocrine-Related Cancer - Tập 25 Số 3 - Trang 309-322 - 2018
Marianne Pavel, David J. Gross, Marta Benavent, Petros Perros, Rajaventhan Srirajaskanthan, Richard R.P. Warner, Matthew H. Kulke, Lowell Anthony, Pamela L. Kunz, Dieter Hörsch, Martin O. Weickert, Pablo Lapuerta, Wenjun Jiang, Kenneth Kassler-Taub, Suman Wason, Rosanna Fleming, Douglas Fleming, Rocio García‐Carbonero
Telotristat ethyl, a tryptophan hydroxylase inhibitor, was efficacious and well tolerated in the phase 3 TELESTAR study in patients with carcinoid syndrome (CS) experiencing ≥4 bowel movements per day (BMs/day) while on somatostatin analogs (SSAs). TELECAST, a phase 3 companion study, assessed the safety and efficacy of telotristat ethyl in patients with CS (diarrhea, flushing, abdominal p...... hiện toàn bộ
Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors
Endocrine-Related Cancer - Tập 22 Số 1 - Trang 1-9 - 2015
Mauro Cives, Pamela L. Kunz, Brian Morse, Domenico Coppola, Michael J. Schell, Tiffany Campos, Phuong Nguyen, Prachi Nandoskar, Vilay H. Khandelwal, Jonathan Strosberg
Pasireotide long-acting repeatable (LAR) is a novel somatostatin analog (SSA) with avid binding affinity to somatostatin receptor subtypes 1, 2, 3 (SSTR1,2,3) and 5 (SSTR5). Results from preclinical studies indicate that pasireotide can inhibit neuroendocrine tumor (NET) growth more robustly than octreotidein vitro. This ...... hiện toàn bộ
Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study
Endocrine-Related Cancer - Tập 23 Số 3 - Trang 191-199 - 2016
Martyn Caplin, Marianne Pavel, Jarosław B. Ćwikła, Alexandria T. Phan, Markus Raderer, Eva Sedláčková, Guillaume Cadiot, Edward M. Wolin, Jaume Capdevila, Lucy Wall, Guido Rindi, Alison Langley, Séverine Martinez, Edda Gomez-Panzani, Philippe Ruszniewski, _ _
In the CLARINET study, lanreotide Autogel (depot in USA) significantly prolonged progression-free survival (PFS) in patients with metastatic pancreatic/intestinal neuroendocrine tumours (NETs). We report long-term safety and additional efficacy data from the open-label extension (OLE). Patients with metastatic grade 1/2 (Ki-67 ≤10%) non-functioning NET and documented baseline tumour-progre...... hiện toàn bộ
Circulating tumor cells and miRNAs as prognostic markers in neuroendocrine neoplasms
Endocrine-Related Cancer - Tập 24 Số 6 - Trang R223-R237 - 2017
Maria Chiara Zatelli, Erika Grossrubatscher, Elia Guadagno, Concetta Sciammarella, Antongiulio Faggiano, Annamaria Colao
The prognosis of neuroendocrine neoplasms (NENs) is widely variable and has been shown to associate with several tissue- and blood-based biomarkers in different settings. The identification of prognostic factors predicting NEN outcome is of paramount importance to select the best clinical management for these patients. Prognostic markers have been intensively investigated, also taking adva...... hiện toàn bộ
Blood and tissue neuroendocrine tumor gene cluster analysis correlate, define hallmarks and predict disease status
Endocrine-Related Cancer - Tập 22 Số 4 - Trang 561-575 - 2015
Mark Kidd, Ignat Drozdov, Irvin M. Modlin
A multianalyte algorithmic assay (MAAA) identifies circulating neuroendocrine tumor (NET) transcripts (n=51) with a sensitivity/specificity of 98%/97%. We evaluated whether blood measurements correlated with tumor tissue transcript analysis. The latter were segregated into gene clusters (GC) that defined clinical ‘hallmarks’ of neoplasia. A MAAA/cluster integrate...... hiện toàn bộ
MicroRNAs associated with small bowel neuroendocrine tumours and their metastases
Endocrine-Related Cancer - Tập 23 Số 9 - Trang 711-726 - 2016
H. Miller, Adam E. Frampton, Anna Malczewska, Silvia Ottaviani, Euan A. Stronach, Rashpal Flora, Daniel Kaemmerer, Gert Schwach, Roswitha Pfragner, Omar Faiz, Beata Kos‐Kudła, George B. Hanna, Justin Stebbing, Leandro Castellano, Andrea Frilling
Novel molecular analytes are needed in small bowel neuroendocrine tumours (SBNETs) to better determine disease aggressiveness and predict treatment response. In this study, we aimed to profile the global miRNome of SBNETs, and identify microRNAs (miRNAs) involved in tumour progression for use as potential biomarkers. Two independent miRNA profiling experiments were performed (...... hiện toàn bộ
Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study
Endocrine-Related Cancer - Tập 19 Số 5 - Trang 657-666 - 2012
Larry K. Kvols, Kjell E. Öberg, Thomas M. O’Dorisio, Pharis Mohideen, Wouter W. de Herder, Rudolf Arnold, Ke Hu, Yilong Zhang, Gareth Hughes, Lowell Anthony, Bertram Wiedenmann
Pasireotide (SOM230) is a novel multireceptor-targeted somatostatin (sst) analog with high binding affinity for sst receptor subtype 1, 2, 3 (sst1,2,3) and sst5. Because of this binding profile, pasireotide may offer symptom control in patients with neuroendocrine tumors (NETs) and carcinoid syndrome no longer responsive to octreotide LAR. This was...... hiện toàn bộ
Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma
Endocrine-Related Cancer - Tập 13 Số 4 - Trang 1213-1221 - 2006
Giovanni Capretti, Rossella Bettini, Edoardo Missiaglia, William Mantovani, Irene Dalai, P. Capelli, M Ferdeghini, P. Pederzoli, Aldo Scarpa, Massimo Falconi
About 40% of nonfunctioning pancreatic endocrine carcinomas (NF-PEC) cannot be cured by surgery due to advanced stage disease. Somatostatin analogues have been proposed as first line therapy in these cases. We performed a prospective phase IV study to assess the efficacy of octreotide in advanced NF-PEC and identify factors predictive of response to therapy. Twenty-one consecutive patients...... hiện toàn bộ
Tổng số: 65   
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7